Credit Suisse’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Credit Suisse’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-96,567	Closed	-$2.23M	–	4716
2020 Q4	$2.23M	Buy	+96,567	New	+$1.22M	﹤0.01%	2740

Credit Suisse's PRVL Position: Q1 2021 in Review

Credit Suisse sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 96,567 shares — an estimated $2.23M sold.

Credit Suisse first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $2.23M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Credit Suisse reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Credit Suisse sold 96,567 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $2.23M.
Credit Suisse first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Credit Suisse's Prevail Therapeutics Inc. Common Stock position peaked at $2.23M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.